Hosted on MSN
Cabaletta Bio Presents Early Clinical Data From RESET-PV Trial Showing Rese-Cel Activity Without Preconditioning
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) presented initial data from its ongoing RESET-PV™ trial evaluating rese-cel (resecabtagene autoleucel, formerly CABA-201) in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback